November 2023 Br J Cardiol 2023;30:153–6 doi:10.5837/bjc.2023.044
Prashasthi Devaiah, Sava Handjiev, Jacob George
Introduction Hypercholesterolaemia, characterised by elevated serum total cholesterol and low-density lipoprotein (LDL), is a crucial factor for atherosclerosis and for the development of cardiovascular diseases (CVD). The hepatic protease proprotein convertase subtilisin/kexin type 9 (PCSK9) targets LDL-receptors for destruction.1,2 Removal of LDL from the blood stream is aided by increased expression of LDL-receptors.3 Statins have been proven to effectively lower LDL-cholesterol (LDL-C) levels and reduce CVD events in many high cardiovascular risk cohorts via 3-hydroxy-3-methylglutaryl coenzyme A (HMG Co-A) reductase inhibition. However, a
June 2015 Br J Cardiol 2015;22:61–2
BJCardio Staff
Cholesterol lowering significantly reduces stroke in the elderly Use of cholesterol lowering drugs (statins and fibrates) is associated with a one third lower risk of stroke in older adults without previous disease, finds a study published in the BMJ. A research team based in France set out to determine the association between use of lipid-lowering drugs in healthy older people and long-term risk of coronary heart disease and stroke. They tracked 7,484 men and women (average age 74 years) with no known history of vascular events, such as heart attacks and strokes, living in three French cities (Bordeaux, Dijon and Montpellier). After an aver
May 2008 Br J Cardiol 2008;15:158–60
Rajesh K Nair, Rangaprasad L Karadi, Eric S Kilpatrick
Introduction It is estimated that 2.5 million patients in the UK currently take statin drugs for both primary and secondary prevention of vascular disease, and this number is likely to rise substantially with the lowering of treatment thresholds.1 As an increasing number of patients become eligible for lipid-lowering treatment, there is an increasing number who appear to be intolerant to individual statins. Indeed, though statins are known to be well tolerated and safe as elucidated in clinical trials, in the real world the incidence of statin intolerance due to non-severe side effects may well be underestimated.2,3 Since differences in the k
November 2006 Br J Cardiol 2006;13:411-8
BJCardio editorial team
No content available
March 2006 Br J Cardiol 2006;13:131-6
H Robert Superko
No content available
January 2006 Br J Cardiol 2006;13:72-6
Alan Middleton, Ahmet Fuat
No content available
November 2004 Br J Cardiol 2004;11:421-3
Michael D Feher
No content available
May 2004 Br J Cardiol 2004;11:205-10
Stephen Chapman, Elly Reeve, David Price, Giri Rajaratnam, Richard Neary
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits
